We utilized single intravitreal injection of L6-F4-2, analogous to intravitreal administration of VEGF inhibitors for macular degeneration and diabetic retinopathy65, in contrast to systemic treatment of retinal phenotypes with FZD4-selective WNT surrogates such as F4L5.1328. This evidence concerns the gene VEGFA and macular degeneration.